Zentalis Pharmaceuticals (ZNTL) EPS (Weighted Average and Diluted) (2019 - 2026)
Zentalis Pharmaceuticals' quarterly EPS (Weighted Average and Diluted) came in at -$0.5 in Q1 2026, up 25.37% year-on-year from -$0.4 in Q1 2025, and down 2.04% quarter-over-quarter from -$0.49 in Q4 2025.
Zentalis Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 8 years, with the latest figure at -$0.5 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 25.37% year-over-year to -$0.5; the trailing twelve-month figure through Mar 2026 stood at -$1.73 (up 44.73% YoY), and the FY2025 full-year result was -$1.91, up 18.03% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.5, down from -$0.49 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.14 in Q1 2024, with the low at -$1.85 in Q2 2023.
- Average EPS (Weighted Average and Diluted) over 5 years is -$0.81, with a median of -$0.79 recorded in 2023.
- Year-over-year, EPS (Weighted Average and Diluted) sank 966.67% in 2022 and soared 113.08% in 2024.
- Tracing ZNTL's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.92 in 2022, then increased by 9.78% to -$0.83 in 2023, then gained by 20.48% to -$0.66 in 2024, then gained by 25.76% to -$0.49 in 2025, then decreased by 2.04% to -$0.5 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.5 (Q1 2026), -$0.49 (Q4 2025), and -$0.37 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | -0.50 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.50 |
| Dec 31, 2025 | -0.49 |
| Sep 30, 2025 | -0.37 |
| Jun 30, 2025 | -0.37 |
| Mar 31, 2025 | -0.67 |
| Dec 31, 2024 | -0.66 |
| Sep 30, 2024 | -0.56 |
| Jun 30, 2024 | -1.24 |
| Mar 31, 2024 | 0.14 |
| Dec 31, 2023 | -0.83 |
| Sep 30, 2023 | -0.79 |
| Jun 30, 2023 | -1.85 |
| Mar 31, 2023 | -1.07 |
| Dec 31, 2022 | -0.92 |
| Sep 30, 2022 | -0.96 |
| Jun 30, 2022 | -1.34 |
| Mar 31, 2022 | -1.31 |
| Dec 31, 2021 | -1.11 |
| Sep 30, 2021 | -0.09 |
| Jun 30, 2021 | -1.34 |
| Mar 31, 2021 | -1.24 |
| Dec 31, 2020 | -1.01 |
| Sep 30, 2020 | -0.91 |
| Jun 30, 2020 | -0.78 |
| Mar 31, 2020 | -2.88 |
| Dec 31, 2019 | -2.60 |